Windtree announces trial design of Phase 2b study of Istaroxime published
PremiumThe FlyWindtree announces trial design of Phase 2b study of Istaroxime published
1M ago
Windtree Therapeutics Appoints New Senior VP and CFO
Premium
Company Announcements
Windtree Therapeutics Appoints New Senior VP and CFO
1M ago
Windtree Therapeutics to hold a virtual investor day
Premium
The Fly
Windtree Therapeutics to hold a virtual investor day
1M ago
Windtree Therapeutics completes enrollment of Phase 2b study of istaroxime
PremiumThe FlyWindtree Therapeutics completes enrollment of Phase 2b study of istaroxime
2M ago
Windtree Therapeutics files to sell 26.67M shares of common stock for holders
Premium
The Fly
Windtree Therapeutics files to sell 26.67M shares of common stock for holders
3M ago
Windtree Therapeutics reports Q2 EPS ($20.91) vs. ($29.47) last year
Premium
The Fly
Windtree Therapeutics reports Q2 EPS ($20.91) vs. ($29.47) last year
3M ago
Windtree Therapeutics Inc trading halted, volatility trading pause
PremiumThe FlyWindtree Therapeutics Inc trading halted, volatility trading pause
3M ago
Windtree Therapeutics provides update on istaroxime development
Premium
The Fly
Windtree Therapeutics provides update on istaroxime development
4M ago
Windtree Therapeutics Raises Funds Through Strategic Securities Placement
Premium
Company Announcements
Windtree Therapeutics Raises Funds Through Strategic Securities Placement
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100